US Interchangeability ‘Irrelevant’ And ‘Makes No Sense’ Says Sandoz

CEO And North America Head Discuss Evolving FDA Approach To Biosimilars

 
• By Dave Wallace
  
Syringe and vial with question mark
The FDA’s initial approach to interchangeability “makes no sense whatsoever” to Sandoz CEO Richard Saynor • Source: Shutterstock

More from Biosimilars

More from Products